SIA
NVO

Stancorp Investment Advisers’s Novo Nordisk NVO Stock Holding History

Stancorp Investment Advisers’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$7K Hold
280
– – ﹤0.01% 501
2014
Q4 		$6K Buy
+280
New +$6.25K ﹤0.01% 504

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Stancorp Investment Advisers's NVO Position: Q1 2015 in Review

Stancorp Investment Advisers held its Novo Nordisk (NVO) position steady in Q1 2015 at 280 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #501.

Stancorp Investment Advisers first reported a position in NVO in Q4 2014 and has held it in 2 quarters since. 505 funds tracked by Wall St. Rank hold NVO as of Q1 2015.

  • Stancorp Investment Advisers held 280 shares of Novo Nordisk worth $7K as of Q1 2015.
  • Stancorp Investment Advisers left its Novo Nordisk share count unchanged in Q1 2015.
  • Novo Nordisk made up ﹤0.01% of Stancorp Investment Advisers's portfolio in Q1 2015, its #501 holding.
  • Stancorp Investment Advisers first reported a position in Novo Nordisk in Q4 2014 and has held it in 2 quarters since.
  • 505 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2015.

Based on Stancorp Investment Advisers's 13F filing for Q1 2015, filed 13 May 2015.